Litcius/Paper detail

Efficacy of intravenous NEPA, a fixed NK1/5-HT3 receptor antagonist combination, for the prevention of chemotherapy-induced nausea and vomiting (CINV) during cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy: A review of phase 3 studies

Matti Aapro, Rudolph M. Navari, Eric Roeland, Li Zhang, Lee S. Schwartzberg

2020Critical Reviews in Oncology/Hematology10 citationsDOIOpen Access PDF

Abstract

RA regimens due to its lack of associated hypersensitivity and injection-site reactions.

Topics & Concepts

PalonosetronAntiemeticChemotherapy-induced nausea and vomitingMedicineCyclophosphamideNauseaVomitingChemotherapyAnthracyclineOncologyPharmacologyAnesthesiaInternal medicineCancerBreast cancerNausea and vomiting managementAnesthesia and Pain ManagementSympathectomy and Hyperhidrosis Treatments
Efficacy of intravenous NEPA, a fixed NK1/5-HT3 receptor antagonist combination, for the prevention of chemotherapy-induced nausea and vomiting (CINV) during cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy: A review of phase 3 studies | Litcius